 |
| Covid-19 vaccine developed jointly by AstraZeneca and researchers at Oxford University © AFP=News1 |
AstraZeneca, a British pharmaceutical company, announced that it has discovered a’winning formula’ that can maximize the efficacy of the novel coronavirus infection (Corona 19) vaccine.
According to the AFP news agency on the 27th, Pascal Sorio AstraZeneca’s chief executive officer (CEO) said in an interview with the Sunday Times that the company’s vaccine is “100% protected” against the aggravation of Corona 19.
CEO Sorio said, “As a result of the clinical trial, two injections showed similar efficacy of the vaccine to other competitors. This data will be released at some point in the future.”
Among pharmaceutical companies that previously announced the results of phase 3 clinical trials, the vaccine of Pfizer and Bioentech is known to be 95% effective and the vaccine of Modena is 94.5%.
AstraZeneca’s vaccine showed an average of 70% efficacy as a result of the initial phase 3 clinical analysis, but it was criticized for being less reliable as it showed 90% efficacy when the dosage was changed to half.
Accordingly, AstraZeneca announced that it would revise and resume clinical trials and conduct a trial to find the maximum efficacy by varying the dosage.
The UK Daily Telegraph said the vaccine, which was jointly developed by researchers at AstraZeneca and Oxford University, is expected to be approved by the UK Medicines and Health Care Products Authority (MHRA) on the 28th.
Unlike Pfizer or Modena vaccines that use mRNA technology, AstraZeneca’s vaccine plays a role in helping to form antibodies by inserting the mRNA code into a weaker version of the chimpanzee virus.
AstraZeneca said it could produce 200 million doses of vaccine worldwide by the end of the year, and more than 700 million doses by the end of March next year.